Johnson & Johnson Pens Alzheimer’s Gene Therapy Pact With the University of Pennsylvania

The pharmaceutical company Johnson & Johnson has formed an Alzheimer’s gene therapy research pact with the University of Pennsylvania. The partnership brings together J&J’s anti-Alzheimer’s antibodies and the university’s adeno-associated viruses (AAVs) in a bid to open up a new frontier in the fight against the disease.

The collaboration aims to use AAV viral delivery to express therapeutic antibodies that target the main pathological hallmarks of Alzheimer’s disease. The use of AAV as a gene delivery method has the potential to transform the way biologic therapies are administered for Alzheimer’s and other brain conditions, opening up novel approaches to treating many devastating neurological diseases. JPI will have exclusive global rights to commercialize products developed under this agreement.

J&J is also working with Dermala, a resident of the San Diego JLABS site, on microbiome-derived treatments for skin conditions and is collaborating with a GPCR expert to discover drugs against obesity and other metabolic diseases. The collaborations are part of a big network of alliances J&J has built up in recent years as it has tried to hit upon a more effective way of accessing innovation.



Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s